Cabergoline
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329208

CAS#: 81409-90-7

Description: Cabergoline, also known as Cabaser and CG-101, is a dopamine D2 receptor agonist used for prolactinoma treatment. Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels.


Price and Availability

Size
Price

10mg
USD 300
Size
Price

50mg
USD 1200
Size
Price

Cabergoline (Cabaser, CG-101) purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329208
Name: Cabergoline
CAS#: 81409-90-7
Chemical Formula: C26H37N5O2
Exact Mass: 451.2947
Molecular Weight: 451.615
Elemental Analysis: C, 69.15; H, 8.26; N, 15.51; O, 7.09


Synonym: Cabergoline; CG-101; FCE-21336; CG 101; FCE 21336; CG101; FCE21336; Cabaser; Cabaseril

IUPAC/Chemical Name: (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide

InChi Key: KORNTPPJEAJQIU-KJXAQDMKSA-N

InChi Code: InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

SMILES Code: O=C(NCC)N(C([C@H](C[C@@]12[H])CN(CC=C)[C@]1([H])CC3=CNC4=C3C2=CC=C4)=O)CCCN(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Şahin N, Apaydın N, Töz E, Sivrikoz ON, Genç M, Turan GA, Cengiz H, Eskicioğlu F. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch Gynecol Obstet. 2016 May;293(5):1101-6. doi: 10.1007/s00404-015-3987-4. PubMed PMID: 26690356.

2: Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas. Neurol Res. 2015 Apr;37(4):341-6. doi: 10.1179/1743132814Y.0000000457. PubMed PMID: 25376133.

3: Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015 Nov;3(11):906-13. doi: 10.1016/S2213-8587(14)70212-8. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Nov;3(11):e10. PubMed PMID: 25466526.

4: Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015 Oct;18(5):745-51. doi: 10.1007/s11102-014-0617-2. Review. PubMed PMID: 25500765.

5: Vroonen L, Lancellotti P, Garcia MT, Dulgheru R, Almanza M, Maiga I, Magne J, Petrossians P, Auriemma R, Daly AF, Beckers A. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine. 2016 Oct 5. PubMed PMID: 27709470.

6: Puig-Domingo M, Soto A, Venegas E, Vilchez R, Blanco C, Cordido F, Lucas T, Marazuela M, Casany R, Cuatrecasas G, Fajardo C, Gálvez MÁ, Maraver S, Martín T, Romero E, Paja M, Picó A, Bernabeu I, Resmini E; ACROCOMB study group.. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Endocrinol Nutr. 2016 Oct;63(8):397-408. doi: 10.1016/j.endonu.2016.05.010. English, Spanish. PubMed PMID: 27448708.

7: Akman L, Sahin G, Erbas O, Aktug H, Akdogan A, Goker EN, Taskiran D, Tavmergen E. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model. Gynecol Endocrinol. 2015 May;31(5):369-73. doi: 10.3109/09513590.2014.1000849. PubMed PMID: 25599748.

8: Fouda UM, Sayed AM, Elshaer HS, Hammad BE, Shaban MM, Elsetohy KA, Youssef MA. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. J Ovarian Res. 2016 May 17;9(1):29. doi: 10.1186/s13048-016-0237-8. PubMed PMID: 27184139; PubMed Central PMCID: PMC4869387.

9: Hollander AB, Pastuszak AW, Hsieh TC, Johnson WG, Scovell JM, Mai CK, Lipshultz LI. Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis. Sex Med. 2016 Mar;4(1):e28-33. doi: 10.1016/j.esxm.2015.09.001. PubMed PMID: 26944776; PubMed Central PMCID: PMC4822480.

10: AlSaad D, ElSalem S, Abdulrouf PV, Thomas B, Alsaad T, Ahmed A, AlHail M. A retrospective drug use evaluation of cabergoline for lactation inhibition at a tertiary care teaching hospital in Qatar. Ther Clin Risk Manag. 2016 Feb 9;12:155-60. doi: 10.2147/TCRM.S96298. PubMed PMID: 26929627; PubMed Central PMCID: PMC4754102.

11: Burman P, Edén-Engström B, Ekman B, Karlsson FA, Schwarcz E, Wahlberg J. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016 Jan;174(1):17-24. doi: 10.1530/EJE-15-0807. PubMed PMID: 26582653.

12: Meinel J, Radad K, Rausch WD, Reichmann H, Gille G. Cabergoline protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture. Folia Neuropathol. 2015;53(1):29-40. PubMed PMID: 25909873.

13: Andrysiak-Mamos E, Kaźmierczyk-Puchalska A, Zochowska E, Sowińska-Przepiera E, Sagan L, Kojder I, Syrenicz A. Evaluaton of therapy with cabergoline in men with macroprolactinoa. Pomeranian J Life Sci. 2015;61(3):263-9. PubMed PMID: 27344867.

14: Koganemaru G, Abe H, Kuramashi A, Ebihara K, Matsuo H, Funahashi H, Yasuda K, Ikeda T, Nishimori T, Ishida Y. Effects of cabergoline and rotigotine on tacrine-induced tremulous jaw movements in rats. Pharmacol Biochem Behav. 2014 Nov;126:103-8. doi: 10.1016/j.pbb.2014.09.015. PubMed PMID: 25265240.

15: Bahar A, Kashi Z, Daneshpour E, Akha O, Ala S. Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial. Medicine (Baltimore). 2016 Oct;95(40):e4818. PubMed PMID: 27749534.